Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab

(MedPage Today) -- SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) antibody-positive, data from the MINT...